You are here: - » English » Software & AI Development

Software & AI Development

Digitineers is proud to be a research based Digital Health Company. Our Medical Devices possess a strong background of scientific evidence.

We are experts for medical domains, medical data domains and medical software achitecture. We work with partnered software and AI engineers at the cutting edge of digital therapeutics (DTx). As a result our produducts may consist of software and of artificial intelligence (AI) alghorithms. Whilst we contribute to a major digitization shift that's already underway it is our philosophy to design products that help patients and preserve humanity.

Our Disan-Products are based on NEGDISAN, our Next-Generation Medical Software Architecture and Development platform. NEGDISAN is a development and production platform for developing, manufacturing and scaling AI-driven (AI DTx, Artificial Intelligence Digital Therapeutics) and non-AI-driven digital therapeutics. The platform is used to produce DTx for patients as well as DTx for use in space. NEGDISAN contributes to a major health care digitization shift that's already underway.


Our Pipeline

Spacedisan: DTx Development for Prevention and Treatment of Inflight and Postflight Space Motion Sickness (SMS)

Problem.
Space motion sickness (SMS) is observed in approximately 70% of astronauts in space and in addition post flight. Even more are expected in future space tourists. Drugs are available but may produce severe adverse events. Furthermore, during longer space missions drugs may lose their efficacy.

Solution.
A DTx (digital therapeutics) possessing the USP to reduce or remove SMS in a higher percentage than drugs or physiotherapy, which is available anytime and anywhere both on earth for preflight prevention and for post flight treatment and in space. In contrast to drugs it does not loose efficacy and does not produce significant adverse events and which in addition covers stress and coping inability. Verti-Disan® will be developed as a digital therapeutics (DTx) to provide a standalone preventive and therapeutic solution.

The device is thought to
--Control a sensory-conflict rearrangement of the terrestrial gravity-related relationship between different inputs that are provided by the eyes, skin, joints, muscles, and especially vestibular receptors in the inner ear.
--Stabilize sensory-motor disturbances.
--Stop illusion of self-motion associated with spatial disorientation.
--Induce head movements in the pitch and roll planes. They result in stabilizing cues being transmitted to the central nervous system regions responsible for central integration of the semi-circular canals (angular acceleration) and the otolith organs (linear acceleration).
--Provide Coriolis cross-coupling stabilization to be achieved by means of sudden ac- and decelerations from constant velocity rotation which are elicited by angular and linear movements, oculomotor and posture responses to optokinetic stimulations, and responses to caloric stimulation.

Space Related Efficacy and Safety. After approval by the relevant State approved Ethics Committee prospective controlled clinical studies are legally and ethically possible investigating feasibility, efficacy and safety of the DTx for prevention and treatment of inflight and postflight vestibular disorders. Studies may start 2023 and may include parabolic flights and space flights. As result the DTx could be a standalone preventive and therapeutic solution for astronauts and space tourists to prevent from and to treat inflight and postflight SMS.